Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, MD as Chief Executive Officer
- Newly appointed CEO has over 20 years’ experience in company building and strategic business development
London UK / Cambridge, MA USA, 25 July 2023 – Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer. The appointment follows the decision of Bertrand Damour to step down as CEO and coincides with the recent appointment of Jeff Albers as Chairman of the Board.
